Onglyza (saxagliptin) comarketed by Bristol-Myers Squibb and AstraZeneca, is FDA-approved to improve glycemic control for the treatment of type 2 diabetes.
Trang Ho
Advertisement
Articles by Trang Ho
Advertisement
Latest Updated Articles
- Rx Product News Profile: A Closer Look at New FDA Actions: Bristol-Myers Squibb's and AstraZeneca's Onglyza
Published: May 11th 2010 | Updated:
Advertisement
Advertisement
